Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 1
2012 2
2013 3
2014 2
2015 2
2016 1
2017 8
2018 6
2019 9
2020 12
2021 26
2022 30
2023 27
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, Lass-Flörl C, Prattes J, Spec A, Thompson GR 3rd, Wiederhold N, Jenks JD. Hoenigl M, et al. Drugs. 2021 Oct;81(15):1703-1729. doi: 10.1007/s40265-021-01611-0. Epub 2021 Oct 9. Drugs. 2021. PMID: 34626339 Free PMC article. Review.
In this review, we describe the mechanisms of drug resistance employed by fungi and extensively discuss the most promising drugs in development, including fosmanogepix (a novel Gwt1 enzyme inhibitor), ibrexafungerp (a first-in-class triterpenoid), olorofim (a novel dihyroo …
In this review, we describe the mechanisms of drug resistance employed by fungi and extensively discuss the most promising drugs in developm …
Ibrexafungerp.
[No authors listed] [No authors listed] 2021 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 34165942 Free Books & Documents. Review.
No information is available on the use of ibrexafungerp during breastfeeding. The drug is over 99% protein bound, so amounts in milk are likely to be very low. If ibrexafungerp is required by the mother of an older infant, it is not a reason to discontinue breastfee …
No information is available on the use of ibrexafungerp during breastfeeding. The drug is over 99% protein bound, so amounts in milk …
Ibrexafungerp: First Approval.
Lee A. Lee A. Drugs. 2021 Aug;81(12):1445-1450. doi: 10.1007/s40265-021-01571-5. Drugs. 2021. PMID: 34313977 Review.
Ibrexafungerp (BREXAFEMME()) is an orally active triterpenoid antifungal drug being developed by SCYNEXIS, Inc. for the treatment of fungal infections. The inhibition of beta-1,3-D glucan synthetase by ibrexafungerp compromises the integrity of fungal cell walls. …
Ibrexafungerp (BREXAFEMME()) is an orally active triterpenoid antifungal drug being developed by SCYNEXIS, Inc. for the treatment of …
Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.
Angulo DA, Alexander B, Rautemaa-Richardson R, Alastruey-Izquierdo A, Hoenigl M, Ibrahim AS, Ghannoum MA, King TR, Azie NE, Walsh TJ. Angulo DA, et al. J Fungi (Basel). 2022 Oct 25;8(11):1121. doi: 10.3390/jof8111121. J Fungi (Basel). 2022. PMID: 36354888 Free PMC article. Review.
Furthermore, ibrexafungerp is approved for use in the USA for the treatment of women with vulvovaginal candidiasis. ...Thus, ibrexafungerp offers promise as a new addition to the clinician's armamentarium against these difficult-to-treat infections....
Furthermore, ibrexafungerp is approved for use in the USA for the treatment of women with vulvovaginal candidiasis. ...Thus, ibrex …
Ibrexafungerp for the treatment of vulvovaginal candidiasis.
Sobel JD. Sobel JD. Drugs Today (Barc). 2022 Apr;58(4):149-158. doi: 10.1358/dot.2022.58.4.3381586. Drugs Today (Barc). 2022. PMID: 35412529 Review.
After 3 decades of azole drug dominance, with few recent new antifungal agents and little progress in VVC management, the first-in-class oral triterpenoid glucan synthase inhibitor agent ibrexafungerp has emerged in the treatment of acute VVC. After reviewing existing trea …
After 3 decades of azole drug dominance, with few recent new antifungal agents and little progress in VVC management, the first-in-class ora …
Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis.
Barnes KN, Yancey AM, Forinash AB. Barnes KN, et al. Ann Pharmacother. 2023 Jan;57(1):99-106. doi: 10.1177/10600280221091301. Epub 2022 May 2. Ann Pharmacother. 2023. PMID: 35502451 Review.
Search terms included ibrexafungerp, SCY-078, and VVC. STUDY SELECTION AND DATA EXTRACTION: All studies including humans and published in English with data assessing the efficacy and safety of ibrexafungerp for the treatment of VVC were evaluated. DATA SYNTHESIS: A …
Search terms included ibrexafungerp, SCY-078, and VVC. STUDY SELECTION AND DATA EXTRACTION: All studies including humans and publishe …
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp.
McCarthy MW. McCarthy MW. Drugs R D. 2022 Mar;22(1):9-13. doi: 10.1007/s40268-021-00376-x. Epub 2021 Dec 27. Drugs R D. 2022. PMID: 34961907 Free PMC article. Review.
On 2 June, 2021, the US Food and Drug Administration approved ibrexafungerp (formerly MK-3118 and SCY-078) for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection. Ibrexafungerp is the first drug approved in a novel antifungal class in m …
On 2 June, 2021, the US Food and Drug Administration approved ibrexafungerp (formerly MK-3118 and SCY-078) for the treatment of vulvo …
Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
Phillips NA, Rocktashel M, Merjanian L. Phillips NA, et al. Drug Des Devel Ther. 2023 Feb 7;17:363-367. doi: 10.2147/DDDT.S339349. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 36785761 Free PMC article. Review.
Ibrexafungerp reaches concentrations up to 9-fold higher in vaginal tissues versus plasma. ...In December 2022, Ibrexafungerp received FDA approval for once monthly dosing to decrease the incidence of RVVC. ...
Ibrexafungerp reaches concentrations up to 9-fold higher in vaginal tissues versus plasma. ...In December 2022, Ibrexafungerp …
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.
Jallow S, Govender NP. Jallow S, et al. J Fungi (Basel). 2021 Feb 25;7(3):163. doi: 10.3390/jof7030163. J Fungi (Basel). 2021. PMID: 33668824 Free PMC article. Review.
Ibrexafungerp (formerly SCY-078 or MK-3118) is a first-in-class triterpenoid antifungal or "fungerp" that inhibits biosynthesis of beta-(1,3)-D-glucan in the fungal cell wall, a mechanism of action similar to that of echinocandins. ...In vivo data have shown IBX to be effe …
Ibrexafungerp (formerly SCY-078 or MK-3118) is a first-in-class triterpenoid antifungal or "fungerp" that inhibits biosynthesis of be …
Ibrexafungerp: A novel oral glucan synthase inhibitor.
Davis MR, Donnelley MA, Thompson GR. Davis MR, et al. Med Mycol. 2020 Jul 1;58(5):579-592. doi: 10.1093/mmy/myz083. Med Mycol. 2020. PMID: 31342066 Review.
Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. ...
Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. ...
132 results